Page last updated: 2024-09-03
tak 044 and atrasentan
tak 044 has been researched along with atrasentan in 1 studies
Compound Research Comparison
Studies (tak 044) | Trials (tak 044) | Recent Studies (post-2010) (tak 044) | Studies (atrasentan) | Trials (atrasentan) | Recent Studies (post-2010) (atrasentan) |
---|---|---|---|---|---|
105 | 8 | 2 | 358 | 41 | 108 |
Protein Interaction Comparison
Protein | Taxonomy | tak 044 (IC50) | atrasentan (IC50) |
---|---|---|---|
Endothelin receptor type B | Homo sapiens (human) | 0.2221 | |
Endothelin-1 receptor | Homo sapiens (human) | 0.0001 | |
Endothelin-1 receptor | Rattus norvegicus (Norway rat) | 0.0002 | |
Endothelin receptor type B | Sus scrofa (pig) | 0.315 |
Research
Studies (1)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Berens, KL; Blok, N; Bourgoyne, AR; Brock, TA; Bui, H; Decker, ER; Dixon, RA; Holland, GW; Knowles, V; Wang, J; Wu, C; You, TJ | 1 |
Trials
1 trial(s) available for tak 044 and atrasentan
Article | Year |
---|---|
Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl)thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonist.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Biological Availability; Dose-Response Relationship, Drug; Double-Blind Method; Endothelin A Receptor Antagonists; Humans; Isoxazoles; Ligands; Male; Models, Molecular; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Structure-Activity Relationship; Sulfones | 2004 |